NASDAQ:ADAP Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free ADAP Stock Alerts $1.01 +0.03 (+3.06%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.95▼$1.0850-Day Range$0.90▼$1.7552-Week Range$0.42▼$2.05Volume694,241 shsAverage Volume1.33 million shsMarket Capitalization$1.00 billionP/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Adaptimmune Therapeutics alerts: Email Address Adaptimmune Therapeutics MarketRank™ Stock AnalysisAnalyst RatingSell1.00 Rating ScoreUpside/Downside147.5% Upside$2.50 Price TargetShort InterestHealthy0.32% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.49) to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.04 out of 5 starsMedical Sector782nd out of 910 stocksBiological Products, Except Diagnostic Industry136th out of 154 stocks 2.5 Analyst's Opinion Consensus RatingAdaptimmune Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAdaptimmune Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.32% of the outstanding shares of Adaptimmune Therapeutics have been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adaptimmune Therapeutics has recently increased by 2.89%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAdaptimmune Therapeutics does not currently pay a dividend.Dividend GrowthAdaptimmune Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADAP. Previous Next 2.4 News and Social Media Coverage News SentimentAdaptimmune Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Adaptimmune Therapeutics this week, compared to 2 articles on an average week.Search Interest9 people have searched for ADAP on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptimmune Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.44% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.37% of the stock of Adaptimmune Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adaptimmune Therapeutics are expected to grow in the coming year, from ($0.49) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptimmune Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptimmune Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptimmune Therapeutics has a P/B Ratio of 25.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Adaptimmune Therapeutics Stock (NASDAQ:ADAP)Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Read More ADAP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADAP Stock News HeadlinesApril 21, 2024 | americanbankingnews.comAdaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Up 12.4%April 19, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week DownApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 17, 2024 | americanbankingnews.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.16April 16, 2024 | markets.businessinsider.comMaintaining Buy Rating on Adaptimmune Therapeutics Post-Genentech Collaboration TerminationApril 14, 2024 | americanbankingnews.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $1.29April 12, 2024 | bizjournals.comAdaptimmune shares drop as Genentech terminates potential $3B dealApril 12, 2024 | msn.comAdaptimmune falls as Roche strategic collaboration endsApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.March 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV)March 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Viridian Therapeutics (VRDN)March 15, 2024 | benzinga.comPeter W. Sonsini's Net WorthMarch 15, 2024 | finance.yahoo.comADAP Sep 2024 2.500 putMarch 13, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday TradingMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)March 8, 2024 | seekingalpha.comAdaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adaptimmune on Strong Clinical Results and Commercial StrategyMarch 8, 2024 | finance.yahoo.comAdaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 7, 2024 | benzinga.comAdaptimmune Therapeutics Earnings PreviewMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adaptimmune on Upcoming Milestones and Promising Trial ResultsMarch 7, 2024 | finance.yahoo.comAdaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial ResultsMarch 7, 2024 | finance.yahoo.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | investorplace.comADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023March 5, 2024 | markets.businessinsider.comAdaptimmune Therapeutics earnings: here's what Wall Street expectsMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adaptimmune Following Reappointment of Key Executive and Strategic Commercialization PlanFebruary 29, 2024 | investing.comAdaptimmune reappoints Cintia Piccina as chief commercial officerFebruary 28, 2024 | finance.yahoo.comADAP Apr 2024 1.500 putSee More Headlines Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/23/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADAP CUSIPN/A CIK1621227 Webwww.adaptimmune.com Phone441235430000Fax44-12-3543-0001Employees449Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$4.00 Low Stock Price Target$1.00 Potential Upside/Downside+147.5%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,870,000.00 Net Margins-188.90% Pretax Margin-186.68% Return on Equity-155.39% Return on Assets-43.42% Debt Debt-to-Equity RatioN/A Current Ratio2.85 Quick Ratio2.85 Sales & Book Value Annual Sales$60.28 million Price / Sales16.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book25.25Miscellaneous Outstanding Shares994,210,000Free Float870,533,000Market Cap$1.00 billion OptionableOptionable Beta2.39 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Adrian G. Rawcliffe (Age 52)CEO, Principal Accounting Officer & Director Comp: $693.64kMr. Gavin Hilary James Wood ACA (Age 54)BA (Hons), Chief Financial Officer Comp: $508.22kMr. William C. Bertrand Jr. (Age 59)Esq., J.D., Chief Operating Officer Comp: $573.8kDr. Elliot Norry B.A. (Age 60)M.D., Chief Medical Officer Comp: $549.05kMs. Cintia Piccina Pharm.D. (Age 50)Chief Commercial Officer Comp: $597.44kDr. Helen Katrina Tayton-Martin MBA (Age 57)Ph.D., Co-Founder & Chief Business & Strategy Officer Comp: $709.84kMs. Joanna Brewer Ph.D. (Age 48)Chief Scientific Officer Dr. Juli P. Miller Ph.D.VP of Corporate Affairs & Investor RelationsMs. Kerry SharpSenior VP & General CouncilDana LynchSenior Director of Corporate CommunicationsMore ExecutivesKey CompetitorsKyverna TherapeuticsNASDAQ:KYTXScholar RockNASDAQ:SRRKBioCryst PharmaceuticalsNASDAQ:BCRXVir BiotechnologyNASDAQ:VIRRelay TherapeuticsNASDAQ:RLAYView All CompetitorsInsiders & InstitutionsJTC Employer Solutions Trustee LtdBought 26,156 shares on 4/19/2024Ownership: 0.003%Key Client Fiduciary Advisors LLCSold 67,965 shares on 4/15/2024Ownership: 0.027%Columbia Advisory Partners LLCBought 15,585 shares on 4/15/2024Ownership: 0.002%Twin Focus Capital Partners LLCBought 55,526 shares on 3/5/2024Ownership: 0.006%Simplex Trading LLCBought 600 shares on 2/2/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ADAP Stock Analysis - Frequently Asked Questions Should I buy or sell Adaptimmune Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" ADAP shares. View ADAP analyst ratings or view top-rated stocks. What is Adaptimmune Therapeutics' stock price target for 2024? 1 Wall Street analysts have issued 12 month target prices for Adaptimmune Therapeutics' stock. Their ADAP share price targets range from $1.00 to $4.00. On average, they expect the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 147.5% from the stock's current price. View analysts price targets for ADAP or view top-rated stocks among Wall Street analysts. How have ADAP shares performed in 2024? Adaptimmune Therapeutics' stock was trading at $0.7930 at the beginning of the year. Since then, ADAP stock has increased by 27.4% and is now trading at $1.01. View the best growth stocks for 2024 here. When is Adaptimmune Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ADAP earnings forecast. How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics plc (NASDAQ:ADAP) posted its quarterly earnings data on Wednesday, March, 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.12. The biotechnology company earned $0.23 million during the quarter, compared to analyst estimates of $4.80 million. Adaptimmune Therapeutics had a negative net margin of 188.90% and a negative trailing twelve-month return on equity of 155.39%. What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO? 6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG). When did Adaptimmune Therapeutics IPO? Adaptimmune Therapeutics (ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are Adaptimmune Therapeutics' major shareholders? Adaptimmune Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Key Client Fiduciary Advisors LLC (0.03%), JTC Employer Solutions Trustee Ltd (0.00%) and Columbia Advisory Partners LLC (0.00%). Insiders that own company stock include Adrian Rawcliffe, Cintia Piccina, Elliot Norry, Garry E Menzel, Gavin Wood, John Lunger and William C Bertrand Jr. View institutional ownership trends. How do I buy shares of Adaptimmune Therapeutics? Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADAP) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
